Xywav Should Be Held for at Least 6 Hours Prior to General Anesthesia
Based on the pharmacokinetics of sodium oxybate and standard preoperative fasting guidelines, patients should discontinue Xywav at least 6 hours before scheduled general anesthesia, treating it similarly to solid food intake.
Rationale and Clinical Approach
Pharmacologic Considerations
Xywav (sodium oxybate) is a central nervous system depressant with rapid onset of action—patients typically fall asleep within 5-15 minutes of dosing 1. The medication is administered at bedtime and, when dosed twice nightly, requires a second dose 2.5-4 hours later. The FDA label explicitly states that Xywav must be taken "at least 2 hours after eating" 1, indicating significant interaction with gastric contents and absorption timing.
Application of ASA Fasting Guidelines
The 2017 ASA Practice Guidelines for Preoperative Fasting provide the framework for this recommendation 2:
- Clear liquids: May be ingested up to 2 hours before anesthesia
- Breast milk: Up to 4 hours before anesthesia
- Infant formula: Up to 6 hours before anesthesia
- Light meals: The guidelines note that "fried or fatty foods or meat may prolong gastric emptying time"
Since Xywav is a concentrated oral solution that must be diluted and taken with food restrictions, and given its profound CNS depressant effects, it should be treated more conservatively than clear liquids.
Specific Holding Recommendations
For typical twice-nightly dosing:
- If surgery is scheduled for morning (e.g., 8:00 AM), the patient should skip both the bedtime dose and the middle-of-the-night dose
- Last dose should be at least 6 hours prior to anesthesia induction
For once-nightly dosing regimens:
- Hold the dose if surgery occurs within 6 hours of typical administration time
- For afternoon surgeries, the previous night's dose may be acceptable if taken >8 hours prior
Critical Safety Considerations
CNS Depression Risk: Xywav is contraindicated with other sedative hypnotics and alcohol 1. The FDA label warns that "clinically significant respiratory depression and obtundation has occurred in adult patients taking sodium oxybate at recommended doses" 1. Residual CNS depression could potentiate anesthetic agents and increase perioperative respiratory complications.
Aspiration Risk: While the ASA guidelines don't specifically address medications like Xywav, patients should be assessed for increased aspiration risk, particularly those with:
- Gastroesophageal reflux disease
- Diabetes mellitus or other conditions affecting gastric motility
- History of difficult airway management 2
Communication with Anesthesia Team
Essential information to convey:
- Exact timing of last Xywav dose
- Total nightly dose (can range from 3-9 g per night)
- Whether patient is on once-nightly or twice-nightly regimen
- Any missed doses and patient's baseline sleep/alertness status
Common Pitfalls to Avoid
Don't assume Xywav is like other sleep medications: Unlike typical hypnotics, sodium oxybate has unique pharmacokinetics and profound CNS effects that warrant conservative holding periods
Don't continue Xywav the night before early morning surgery: Even if the last dose was 8+ hours prior, the profound sleep-inducing effects and potential for prolonged sedation argue for holding the medication
Don't forget to document: Clearly document in the preoperative assessment when Xywav was last taken and communicate this directly to the anesthesia team
Postoperative Resumption
The FDA label provides guidance on missed doses: "If the second dose is missed, that dose should be skipped and XYWAV should not be taken again until the next night" 1. After surgery, resumption should be individualized based on:
- Return of normal oral intake
- Adequate pain control without excessive opioid requirements
- Patient fully alert and able to safely take medication at bedtime
- At least 2 hours after eating 1
The 6-hour holding period balances patient safety by minimizing additive CNS depression and aspiration risk while being practical for surgical scheduling.